A very interesting explanatory mechanism for the various manifestations and pathways of Covid progression.
Alveolar epithelial cell type II could be the main target of SARS-CoV-2 virus and COVID-19 development via NF-Kb pathway deregulation: a physio-pathological theory
https://www.sciencedirect.com/science/article...772033303X
“Here we propose a theory by which the main targets for SARS-CoV-2 are the Type II Alveolar Epithelial Cells and the clinical manifestations of the syndrome are a direct consequence of their involvement. We propose the existence of a vicious cycle by which once alveolar damage starts in AEC II cells, the inflammatory state is supported by macrophage pro-inflammatory polarization (M1), cytokines release and by the activation of the NF-κB pathway. If this theory is confirmed, future therapeutic efforts can be directed to target Type 2 alveolar cells and the molecular pathogenic drivers associated with their dysfunction with currently available therapeutic strategies.
[img]
Administer leronlimab to block cytokine storm and block macrophage activation (thanks Drs Seethamraju and Patterson) and the vicious cycle of NK-kB activation is interrupted.
Alveolar epithelial cell type II could be the main target of SARS-CoV-2 virus and COVID-19 development via NF-Kb pathway deregulation: a physio-pathological theory
https://www.sciencedirect.com/science/article...772033303X
“Here we propose a theory by which the main targets for SARS-CoV-2 are the Type II Alveolar Epithelial Cells and the clinical manifestations of the syndrome are a direct consequence of their involvement. We propose the existence of a vicious cycle by which once alveolar damage starts in AEC II cells, the inflammatory state is supported by macrophage pro-inflammatory polarization (M1), cytokines release and by the activation of the NF-κB pathway. If this theory is confirmed, future therapeutic efforts can be directed to target Type 2 alveolar cells and the molecular pathogenic drivers associated with their dysfunction with currently available therapeutic strategies.
[img]Administer leronlimab to block cytokine storm and block macrophage activation (thanks Drs Seethamraju and Patterson) and the vicious cycle of NK-kB activation is interrupted.
